A Delaware jury found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents owned by Scale Biosciences (acquired by 10x Genomics in 2025) tied to methods for identifying multiple epitopes in cells. The jury also upheld the validity of those patents and awarded 10x more than $4.8 million in damages tied to Parse Evercode Whole Transcriptome sales. 10x said it will pursue enhanced damages and attorneys’ fees post-trial and seek a permanent injunction to stop further infringement in the U.S. The verdict specifically cites Parse product sales from February 2021 through June 30, 2026, based on a 14% royalty rate for infringing sales. The case also references a separate earlier dispute in which 10x lost other patent infringement claims, and underscores how rapidly evolving single-cell platforms continue to collide with IP boundaries over multiplexing and readout methods.